Compounded tirzepatide recall pulls 22 lots of copycat Zepbound

A compounding pharmacy called Apothecary Pharma has pulled 22 lots of its copycat Zepbound, according to an FDA notice made public in October. The compounded tirzepatide recall is voluntary, and the FDA placed it in Class II, the middle of its three recall classes. The pharmacy said in the notice that it could not say for certain the drug was safe. For people who get GLP 1 drugs from compounders rather than from the brand makers, the case shows how little outside checking stands behind a compounded vial.

What Apothecary Pharma recalled and when

Apothecary Pharma told the FDA about the compounded tirzepatide recall in September, according to a BioPharma Dive brief published on October 22. Tirzepatide is the active ingredient that Eli Lilly sells as Zepbound for weight loss and as Mounjaro for type 2 diabetes. The recall covers 22 lots. Each lot carries a beyond use date, the last day a compounded drug is meant to be used, and those dates run from October 8 to November 26. Some vials had already passed their date by the time the news broke, while others could stay in home fridges for weeks. The reports do not say where the lots were shipped, which clinics or online brands sold them, or how many patients received one.

The notice gives only a short reason. As BioPharma Dive described it, Apothecary stated that it could not fully guarantee the safety of the medicine. That is unusual wording for a recall. The public reports name no failed test, no contamination finding and no injury linked to the lots, and the FDA has not said that anyone was harmed. A voluntary recall is one the firm starts on its own; the FDA then reviews it and assigns a risk class. The table below sets out what has been confirmed so far, drawn from the FDA notice and the BioPharma Dive report. Other details, such as where the lots went, have not been published in the sources Peptide Town checked.

What a Class II recall means for patients

A Class II recall sits in the middle tier of the FDA's system, below the most serious Class I. Under FDA rules, as quoted by BioPharma Dive, a Class II product is one whose use "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." In plain words, the agency judged that serious harm from these lots is unlikely, though it cannot be ruled out. The class is a risk rating, not a finding that patients were injured. It also does not tell readers what went wrong in production or storage. That detail usually sits in the firm's own recall letter to customers, which has not been published in the sources Peptide Town reviewed.

The class is a risk rating, not a finding that patients were injured.

For a patient, the practical step is to check the lot number on any compounded vial with the pharmacy or prescriber that supplied it. Many people who get these drugs through an online clinic never see the pharmacy name, because the telehealth brand sits in front of it. In its guidance for telehealth companies, the FDA says compounded drugs get no agency review for safety, effectiveness or quality before they reach patients. That makes a recall notice one of the few public signals that something may be wrong with a batch. Anyone with new symptoms after an injection should contact a clinician, and side effects can be reported to the FDA. This story is news reporting, not medical advice.

Why copycat Zepbound is still sold after the shortage

Compounded copies of Zepbound and Novo Nordisk's Wegovy spread while the brand drugs were in shortage, and many telehealth firms offered lower cost versions. Those shortages have since ended. Many sellers kept going anyway by offering personalized treatment plans, a practice that federal law permits, BioPharma Dive reported. A recent Gallup survey, cited by the outlet, found that about one in five Americans taking these drugs use a compounded form. A USC and RAND preprint covered on this site estimated that about 9 million US adults got GLP 1 drugs outside insurance and regular pharmacies, through online prescribers, med spas, compounders, foreign pharmacies or no prescription at all. Those figures suggest a recall of this kind can reach well beyond one pharmacy's customer list.

Lilly and Novo Nordisk, the only makers of FDA licensed GLP 1 obesity drugs, have filed lawsuits against sellers and argue that the quality and safety of copies cannot be guaranteed. BioPharma Dive noted that this market now also includes retatrutide, a Lilly drug that is still experimental. The FDA has restricted a key supply channel for compounders, the outlet added, and in 2025 the agency sent warning letters over GLP 1 ads to online clinics. The compounded tirzepatide recall may give the drugmakers fresh material, since a compounder now says it could not stand behind its own product. Whether courts or regulators will treat one recall as evidence about the wider compounded GLP 1 trade is not known.

What the recall changes for telehealth compounding

For sellers, the compounded tirzepatide recall lands on top of FDA limits on how compounded GLP 1 drugs may be marketed. The agency has told telehealth companies not to describe a compounded drug as a generic or as the same as an approved medicine. It has also warned them not to claim a drug comes from an FDA approved or licensed pharmacy, because the FDA does not approve or license any facility. A recall makes those limits easier for patients to see, since a public notice now shows a compounder pulling its own tirzepatide. The FDA has not said whether it plans to inspect Apothecary or take further action, and the pharmacy has not released any public statement beyond its notice.

The recall also arrives as federal officials move to widen telehealth compounding and pharmacy compounding in another corner of the peptide market. In July, an FDA advisory panel backed broader use of six peptides even without strong evidence of their safety and benefit, and the government has reportedly advanced plans to let specialty pharmacies make them. Peptide Town covered the HHS peptide compounding policy earlier this week. The open question is the same for both groups of drugs. Buyers need a way to tell whether a compounded vial was made to a steady standard when no agency checks it before it ships, and today that check mostly happens after a problem surfaces, through a recall like this one.

Conclusion

The compounded tirzepatide recall is small, 22 lots from one pharmacy, but it is a rare public admission from a compounder that it could not vouch for its own product. Key facts are still missing: where the vials went, what problem was found and whether anyone was hurt. Patients using a compounded GLP 1 drug should confirm their lot with the dispensing pharmacy and ask a prescriber about approved options and coverage. Peptide Town will update this story if the FDA or Apothecary releases more detail.